The present disclosure relates to a fast and simple process for the obtention of high purity immunoglobulins (Igs) or antibodies. These polyclonal antibodies are obtained from egg yolk, representing an alternative way for the acquisition thereof and a renewable and profitable source for the production thereof.

The process described herein encompasses several steps in which low cost, biocompatible and selective precipitating agents can be used in conjunction with an ultrafiltration step.

Antibodies and compositions against GLUT4 and uses thereof are provided herein.

To obtain an anti-PAD2 antibody having excellent PAD2 inhibitory activity. Provided is an anti-PAD2 antibody that specifically binds to positions 341 to 357 of PAD2. Also provided is an anti-PAD2 antibody that specifically binds to a peptide consisting of an amino acid sequence set forth in SEQ ID NO: 1.

This disclosure provides, among other things, a transgenic chicken. In some embodiments, the transgenic chicken comprises B cells in which the endogenous immunoglobulin heavy chain locus comprises: (a) a functional immunoglobulin heavy chain gene comprising a nucleic acid encoding a heavy chain variable domain in which the CDR3 is in the range of 30-60 amino acids in length and comprises at least 2 cysteine residues; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the heavy chain variable domain of (a), wherein the pseudogenes are upstream or downstream of the functional immunoglobulin heavy chain gene.

Provided herein is a transgenic chicken comprising a genome having an endogenous immunoglobulin heavy chain gene in which the IgY CH1 coding sequence is functionally deleted. In certain embodiments, in B cells of the chicken the endogenous immunoglobulin heavy chain gene comprises: (a) a functional immunoglobulin heavy chain gene comprising, in operable linkage, a nucleic acid encoding an antibody heavy chain variable domain and a constant region coding sequence in which the IgY CH1 coding sequence is functionally deleted; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the variable domain of (a), wherein the pseudogenes are upstream of the nucleic acid encoding an antibody heavy chain variable domain of (a).

A composition for treatment of African Swine Fever in swine includes avian-sourced antibodies specific for an African Swine Fever Virus isolate. These antibodies are produced by avian animals immunized against the African Swine Fever Virus isolate and mixed with a protective/reactive matrix obtained from, isolated from, or derived from, non-hyperimmune colostrum.

A method for detecting MERS-CoV at high sensitivity and specificity using IgY antibodies that bind to MERS-CoV N protein, its fragments and domains. Isolated or purified IgY monospecific antibodies to MERS-CoV N protein.

For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substances released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus.

This disclosure provides, among other things, a transgenic animal and a method of using the same to make antibodies that have a common light chain. In certain embodiments, the transgenic animal may comprising a genome comprising a common light chain transgene, wherein the common light chain transgene comprises a non-immunoglobulin light-chain promoter and a common light-chain coding sequence. In certain embodiments, the common light chain is constitutively expressed.

An antibody or an antigen-binding fragment thereof binds to an antigen of the bacterium Candidatus savagella and inhibits the adhesion of the bacterium to intestinal epithelial cells; and/or depletes the bacterium. A drug has the antibody or an antigen-binding fragment thereof. A kit has the antibody or an antigen-binding fragment thereof for reduction of Th17 cell proliferation, Th17 cell differentiation or Th17 cell activity and/or inhibition of the formation of antibodies against endogenous antigens by B cells. The kit can contain an antibiotic. A method for producing the antibody involves immunizing chickens with an immunogenic peptide from an antigen of the bacterium Candidatus savagella, and recovering and purifying the antibodies formed in the chickens or in an egg laid by said chickens. A method for producing the drug involves producing the antibody or an antigen-binding fragment thereof, and formulating the antibody or an antigen-binding fragment thereof as a drug.